journal
Journals Clinical Advances in Hematolog...

Clinical Advances in Hematology & Oncology : H&O

https://read.qxmd.com/read/38805317/new-drug-approvals-for-prostate-cancer
#1
JOURNAL ARTICLE
Ian F Tannock
No abstract text is available yet for this article.
June 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38805316/steap1-as-a-potential-target-for-new-therapies-in-prostate-cancer
#2
JOURNAL ARTICLE
Wm Kevin Kelly
No abstract text is available yet for this article.
June 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38805315/pirtobrutinib-in-relapsed-or-refractory-cll-and-sll
#3
JOURNAL ARTICLE
Jennifer A Woyach
No abstract text is available yet for this article.
June 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38805314/the-evolving-role-of-surgery-in-melanoma
#4
JOURNAL ARTICLE
Vernon K Sondak
No abstract text is available yet for this article.
June 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38805313/antibody-drug-conjugates-in-advanced-lung-cancer-is-this-a-new-frontier
#5
REVIEW
Joshua E Reuss, Samuel Rosner, Benjamin P Levy
Over the past decade, the lung cancer landscape has been dominated by targeted and immunotherapeutic approaches that have drastically shifted treatment paradigms for patients with advanced non-small cell lung cancer (NSCLC). Despite these scientific and clinical advances, there are still many unmet needs underscoring the importance of novel strategies. Antibody-drug conjugates (ADCs) represent one such strategy that is beginning to alter the therapeutic strategies for patients with advanced NSCLC. The rationale of ADCs is simple: selectively deliver cytotoxic payloads through an antibody-mediated process to target antigens expressed by cancer cells, sparing normal tissue and inflicting damage to tumors...
June 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38805312/redefining-the-standard-of-care-for-low-grade-serous-ovarian-cancer
#6
REVIEW
Beryl L Manning-Geist, Tal Cantor, Róisín E O'Cearbhaill, Rachel N Grisham
Low-grade serous carcinoma is a rare epithelial ovarian cancer subtype with distinct clinical, histologic, and molecular features. Improved understanding of this disease subtype has prompted recent advances in treatment options. Although low-grade serous carcinoma historically has been treated following a high-grade serous carcinoma paradigm, new data have called into question the utility of platinum retreatment, addressed the possibility of first-line hormonal treatment, and brought forth therapeutic options targeting the MAPK pathway and cyclin D kinase in low-grade tumors...
June 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38805301/how-best-to-extend-overall-survival-in-metastatic-colorectal-cancer-q-a
#7
JOURNAL ARTICLE
Tanios S Bekaii-Saab, Afsaneh Barzi, Mike Cusnir
No abstract text is available yet for this article.
June 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38805300/sequencing-third-line-therapies-for-metastatic-colorectal-cancer-a-guide-for-determining-which-therapy-to-use-first
#8
JOURNAL ARTICLE
Mike Cusnir
No abstract text is available yet for this article.
June 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38805299/real-world-data-on-sequencing-third-line-therapies-for-metastatic-colorectal-cancer
#9
JOURNAL ARTICLE
Tanios S Bekaii-Saab
No abstract text is available yet for this article.
June 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38805298/review-of-third-line-treatment-strategies-in-refractory-metastatic-colorectal-cancer
#10
REVIEW
Afsaneh Barzi
No abstract text is available yet for this article.
June 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38805297/improving-survival-in-metastatic-colorectal-cancer-through-optimized-patient-selection
#11
REVIEW
Tanios S Bekaii-Saab, Afsaneh Barzi, Mike Cusnir
The systemic treatment options for patients with metastatic colorectal cancer have recently expanded with the US Food and Drug Administration approval of fruquintinib being added to previously approved trifluridine/tipiracil with or without bevacizumab and regorafenib. These therapies are recommended for use based on the initial clinical trials that focused on their safety and efficacy in extending overall survival of patients with refractory metastatic disease, as well as later studies, including the ReDOS study that confirmed the dose-escalation strategy of regorafenib to be key in optimizing duration of therapy and preventing side effects...
June 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38739723/protac-drugs-in-cancer-care
#12
JOURNAL ARTICLE
Peter A Fasching
No abstract text is available yet for this article.
May 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38739722/the-development-of-menin-inhibitors-in-aml-and-all
#13
JOURNAL ARTICLE
Ghayas C Issa
No abstract text is available yet for this article.
May 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38739721/liver-transplant-in-patients-with-metastatic-colorectal-cancer
#14
JOURNAL ARTICLE
Bashar A Aqel
No abstract text is available yet for this article.
May 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38739720/increasing-inclusion-and-equity-for-black-women-in-breast-cancer-clinical-trials
#15
REVIEW
Ammanuel Taye, Ahmed Elkhanany, Erica Stringer-Reasor
Black women diagnosed with breast cancer experience a disproportionately high mortality rate. The disparity in outcomes between Black and White women is multifactorial, with a large portion attributed to lower participation of minorities in clinical trials. The lack of diversity in clinical trials continues to both reflect and contribute to health care inequities, limiting the generalizability of research findings. In addition, women who do not enroll in clinical trials miss out on the standard-of-care or often better patient care provided in these trials...
May 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38739719/immune-checkpoint-inhibitor-therapy-in-locally-advanced-msi-gi-malignancies
#16
REVIEW
Emily C Harrold, Fergus Keane, Andrea Cercek
Locally advanced gastrointestinal (GI) malignancies have conventionally been treated in a multimodal fashion that combines (neo)adjuvant chemotherapy with or without radiation and definitive surgical resection. Clinical data have demonstrated the reduced responsiveness of GI malignancies with microsatellite instability (MSI) to both adjuvant and neoadjuvant systemic chemotherapy when compared with microsatellite stable (MSS) disease. The elevated tumor mutational burden associated with MSI tumors of all types sensitizes these tumors to the effects of immune checkpoint blockade in the metastatic setting, which led to tumor-agnostic approval of immune checkpoint inhibitors in this context...
May 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38739704/improving-outcomes-in-pediatric-ntrk-gene-fusion-positive-solid-tumors-importance-of-genomic-testing-and-targeted-therapy-with-the-trk-inhibitor-larotrectinib
#17
JOURNAL ARTICLE
Theodore W Laetsch
No abstract text is available yet for this article.
May 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38588273/the-role-of-noncovalent-btk-inhibitors-in-the-era-of-covalent-btk-inhibitors
#18
REVIEW
Fateeha Furqan, Nirav N Shah
Despite significantly improving outcomes in patients with B-cell malignancies, covalent Bruton tyrosine kinase (BTK) inhibitors are limited by toxicities and the development of resistance. Some toxicities can be life-threatening, such as cardiotoxicity. These toxicities result from off-target effects of covalent BTK inhibitors and frequently lead to dose reductions and discontinuations of the drug. Noncovalent BTK inhibitors bind BTK in a unique fashion and, to date, have demonstrated an excellent safety profile as well as efficacy against a variety of B-cell malignancies...
April 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38588272/immunotherapy-in-the-treatment-of-advanced-or-recurrent-endometrial-cancer
#19
REVIEW
Juan Francisco Grau-Bejar, Lorena Farinas-Madrid, Carmen García-Duran, David García-Illescas, Roberta Mazzeo, Ana Oaknin
The standard treatment of patients with advanced or recurrent endometrial cancer has not significantly changed over the past few decades, reflecting a major unmet clinical need. Fortunately, the arrival of immune checkpoint inhibition is rapidly changing this dismal scenario. This review discusses the most recent results from clinical trials evaluating the use of immune checkpoint inhibitors, either as monotherapy or in combination therapy, in both the post-platinum and frontline settings. Additionally, a section is devoted to the future clinical development of immune checkpoint inhibitors in advanced or recurrent endometrial cancer...
April 2024: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/38588271/coordination-between-the-fda-and-the-us-patent-and-trademark-office
#20
Kathi Vidal
No abstract text is available yet for this article.
April 2024: Clinical Advances in Hematology & Oncology: H&O
journal
journal
40386
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.